Tsukuba, Japan

Yusuke Adachi

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yusuke Adachi: Innovator in Antibody Development

Introduction

Yusuke Adachi is a notable inventor based in Tsukuba, Japan, recognized for his contributions to the field of biopharmaceuticals. With a focus on developing innovative antibody therapies, he has secured two patents, positioning himself as a key player in the rapidly evolving landscape of medical biotechnology.

Latest Patents

One of Yusuke Adachi's significant contributions is the invention of an anti-human Notch4 antibody. This innovative antibody demonstrates neutralizing activity against human Notch4 and is included in a pharmaceutical composition. The invention arose from the development of a mouse anti-human Notch4 antibody, exhibiting high neutralizing activity and strong binding affinity towards human Notch4. This research involved determining the complementarity determining region (CDR) sequence of the mouse antibody, which facilitated the creation of a humanized antibody, incorporating the variable regions of heavy and light chains alongside the CDR sequence.

Career Highlights

Yusuke Adachi is currently associated with Eisai R&D Management Co., Ltd., where he applies his expertise in antibody engineering and biopharmaceutical development. His work contributes to advancing therapeutics that target crucial pathways in disease mechanisms, showcasing his commitment to improving patient outcomes through innovation.

Collaborations

Throughout his career, Yusuke has collaborated with several notable colleagues, including Yoshimasa Sakamoto and Junji Matsui. These collaborations reflect a team-oriented approach to research and development, emphasizing the importance of shared knowledge and interdisciplinary efforts in the innovation process.

Conclusion

Yusuke Adachi's work in developing targeted antibody therapies marks a significant advancement in biopharmaceuticals. His innovative spirit and collaborative efforts contribute to the ongoing progress in medical science, holding promise for future therapeutic applications in treating human diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…